Flexible vascular occluding device

Information

  • Patent Grant
  • 9125659
  • Patent Number
    9,125,659
  • Date Filed
    Monday, March 18, 2013
    11 years ago
  • Date Issued
    Tuesday, September 8, 2015
    8 years ago
Abstract
A vascular occluding device for modifying blood flow in a vessel, while maintaining blood flow to the surrounding tissue. The occluding device includes a flexible, easily compressible and bendable occluding device that is particularly suited for treating aneurysms in the brain. The neurovascular occluding device can be deployed using a micro-catheter. The occluding device can be formed by braiding wires in a helical fashion and can have varying lattice densities along the length of the occluding device. The occluding device could also have different lattice densities for surfaces on the same radial plane.
Description
FIELD OF THE INVENTION

The invention relates generally to an implantable device that could be used in the vasculature to treat common vascular malformations. More particularly, it relates to a flexible, biocompatible device that can be introduced into the vasculature of a patient to embolize and occlude aneurysms, particularly cerebral aneurysms.


BACKGROUND OF THE INVENTION

Walls of the vasculature, particularly arterial walls, may develop pathological dilatation called an aneurysm. Aneurysms are commonly observed as a ballooning-out of the wall of an artery. This is a result of the vessel wall being weakened by disease, injury or a congenital abnormality. Aneurysms have thin, weak walls and have a tendency to rupture and are often caused or made worse by high blood pressure. Aneurysms could be found in different parts of the body; the most common being abdominal aortic aneurysms (AAA) and the brain or cerebral aneurysms. The mere presence of an aneurysm is not always life-threatening, but they can have serious heath consequences such as a stroke if one should rupture in the brain. Additionally, as is known, a ruptured aneurysm can also result in death.


The most common type of cerebral aneurysm is called a saccular aneurysm, which is commonly found at the bifurcation of a vessel. The locus of bifurcation, the bottom of the V in the Y, could be weakened by hemodynamic forces of the blood flow. On a histological level, aneurysms are caused by damage to cells in the arterial wall. Damage is believed to be caused by shear stresses due to blood flow. Shear stress generates heat that breaks down the cells. Such hemodynamic stresses at the vessel wall, possibly in conjunction with intrinsic abnormalities of the vessel wall, have been considered to be the underlying cause for the origin, growth and rupture of these saccular aneurysms of the cerebral arteries (Lieber and Gounis, The Physics of Endoluminal stenting in the Treatment of Cerebrovascular Aneurysms, Neurol Res 2002: 24: S32-S42). In histological studies, damaged intimal cells are elongated compared to round healthy cells. Shear stress can vary greatly at different phases of the cardiac cycle, locations in the arterial wall and among different individuals as a function of geometry of the artery and the viscosity, density and velocity of the blood. Once an aneurysm is formed, fluctuations in blood flow within the aneurysm are of critical importance because they can induce vibrations of the aneurysm wall that contribute to progression and eventual rupture. For a more detailed description of the above concepts see, for example, Steiger, Pathophysiology of Development and Rupture of Cerebral Aneurysms, Acta Neurochir Suppl 1990: 48: 1-57; Fergueson, Physical Factors in the Initiation, Growth and Rupture of Human Intracranial Saccular Aneurysms, J Neurosurg 1972: 37: 666-677.


Aneurysms are generally treated by excluding the weakened part of the vessel from the arterial circulation. For treating a cerebral aneurysm, such reinforcement is done in many ways: (i) surgical clipping, where a metal clip is secured around the base of the aneurysm; (ii) packing the aneurysm with microcoils, which are small, flexible wire coils; (iii) using embolic materials to “fill” an aneurysm; (iv) using detachable balloons or coils to occlude the parent vessel that supplies the aneurysm; and (v) endovascular stenting. For a general discussion and review of these different methods see Qureshi, Endovascular Treatment of Cerebrovascular Diseases and Intracranial Neoplasms, Lancet. 2004 Mar. 6; 363 (9411):804-13; Brilstra et al. Treatment of Intracranial Aneurysms by Embolization with Coils: A Systematic Review, Stroke 1999; 30: 470-476.


As minimally invasive interventional techniques gain more prominence, microcatheter based approaches for treating neurovascular aneurysms are becoming more prevalent. Micro-catheters, whether flow-directed or wire-directed, are used for dispensing embolic materials, micro coils or other structures (e.g., stents) for embolization of the aneurysm. A microcoil can be passed through a microcatheter and deployed in an aneurysm using mechanical or chemical detachment mechanisms, or be deployed into the parent vessel to permanently occlude it and thus block flow into the aneurysm. Alternatively, a stent could be tracked through the neurovasculature to the desired location. Article by Pereira, History of Endovascular Aneurysms Occlusion in Management of Cerebral Aneurysms; Eds: Le Roux et al., 2004, pp: 11-26 provides an excellent background on the history of aneurysm detection and treatment alternatives.


As noted in many of the articles mentioned above, and based on the origin, formation and rupture of the cerebral aneurysm, it is obvious that the goal of aneurysmal therapy is to reduce the risk of rupture of the aneurysm and thus the consequences of sub-arachnoid hemorrhage. It should also be noted that while preventing blood from flowing into the aneurysm is highly desirable, so that the weakened wall of the aneurysm doesn't rupture, it may also be vital that blood flow to the surrounding structures is not limited by the method used to obstruct blood flow to the aneurysm. Conventional stents developed for treating other vascular abnormalities in the body are ill suited for embolizing cerebral aneurysms. This could lead to all the usual complications when high oxygen consumers, such as brain tissue, are deprived of the needed blood flow.


There are many shortcomings with the existing approaches for treating neurovascular aneurysms. The vessels of the neurovasculature are the most tortuous in the body; certainly more tortuous than the vessels of the coronary circulation. Hence, it is a challenge for the surgeon to navigate the neurovasculature using stiff coronary stents that are sometimes used in the neurovasculature for treating aneurysms. The bending force of a prosthesis indicates the maneuverability of the prosthesis through the vasculature; a lower bending force would imply that the prosthesis is more easily navigated through the vasculature compared to one with a higher bending force. Bending force for a typical coronary stent is 0.05 lb-in (force to bend 0.5 inches cantilever to 90 degree). Hence, it will be useful to have neural prosthesis that is more flexible than existing stents.


Existing stent structures, whether used in coronary vessels or in the neurovasculature (microcoils) are usually straight, often laser cut from a straight tubing or braiding with stiff metallic materials. However, most of the blood vessels are curved. Hence, current stent structures and microcoils impart significant stress on the vessel walls as they try to straighten a curved vessel wall. For a weakened vessel wall, particularly where there is a propensity for an aneurysm formation, this could have disastrous consequences.


As noted earlier, the hemodynamic stress placed on the blood vessels, particularly at the point of bifurcation, leads to weakening of the vessel walls. The most significant source of such stress is the sudden change in direction of the blood flow. Hence, if one were to minimize the sudden change in direction of blood flow, particularly at the location of vessel weakness, it would be beneficial.


Existing approaches to occluding aneurysms could lead to another set of problems. Methods that merely occlude the aneurysm by packing or filling it with embolic material (coils or liquid polymers) do not address the fundamental flow abnormalities that contribute to the formation of aneurysm.


Currently, many different stent structures and stent deployment methods exist. A stent structure could be expanded after being placed intraluminally on a balloon catheter. Alternatively, self-expanding stems could be inserted in a compressed state and expanded upon deployment. All the stents need to have the radial rigidity to maintain patency of the lumen and simultaneously have the longitudinal flexibility to facilitate navigating the tortuous path of the vasculature. For balloon expandable stents, the stent is mounted on a balloon at the distal end of a catheter, the catheter is advanced to the desired location and the balloon is inflated to expand the stent into a permanent expanded condition. The balloon is then deflated and the catheter withdrawn leaving the expanded stent to maintain vessel patency. Because of the potentially lethal consequences of dissecting or rupturing an intracerebral vessel, the use of balloon expandable stents in the brain is fraught with problems. Proper deployment of a balloon expandable stent requires slight over expanding of the balloon mounted stent to embed the stent in the vessel wall and the margin of error is small. Balloon expandable stents are also poorly suited to adapt to the natural tapering of cerebral vessels which taper proximally to distally. If a stent is placed from a parent vessel into a smaller branch vessel the change in diameter between the vessels makes it difficult to safely deploy a balloon expandable stent. A self-expanding stent, where the compressed or collapsed stent is held by an outer restraining sheath over the compressed stent to maintain the compressed state until deployment. At the time of deployment, the restraining outer sheath is retracted to uncover the compressed stent, which then expands to keep the vessel open. Additionally, the catheters employed for delivering such prosthesis are micro-catheters with outer diameter of 0.65 mm to 1.3 mm compared to the larger catheters that are used for delivering the large coronary stents to the coronaries.


Various stent structures and solutions have been suggested for treating cerebral aneurysms. U.S. Pat. No. 6,669,719 (Wallace et al.) describes a stent and a stent catheter for intra-cranial use. A rolled sheet stent is releasably mounted on the distal tip of a catheter. Upon the rolled sheet being positioned at the aneurysm, the stent is released. This results in immediate and complete isolation of an aneurysm and surrounding side branches of the circulatory system and redirecting blood flow away from the aneurysm. A significant drawback of such a system is that the surrounding side branches, along with the target aneurysm, are deprived of the needed blood flow after the stent has been deployed.


U.S. Pat. No. 6,605,110 (Harrison) describes a self-expanding stent for delivery through a tortuous anatomy or for conforming the stent to a curved vessel. This patent describes a stent structure with radially expandable cylindrical elements arranged in parallel to each other and interspersed between these elements and connecting two adjacent cylindrical elements are struts that are bendable. While this structure could provide the necessary flexibility and bendability of the stent for certain applications, it is expensive and complex to manufacture.


U.S. Pat. No. 6,572,646 (Boylan) discloses a stent made up of a super-elastic alloy, such as Ni—Ti alloy (Nitinol), with a low temperature phase that induces a first shape to the stent and a high temperature phase that induces a second shape to the stent with a bend along the length. U.S. Pat. No. 6,689,162 (Thompson) discloses a braided prosthesis that uses strands of metal, for providing strength, and compliant textile strands. The objective of Thompson is to have a prosthesis that combines the structural strength and resiliency of a self-expanding stent and the low permeability of a graft. U.S. Pat. No. 6,656,212 (Denardo et al.) describes an intravascular flow modifier that allows microcoil introduction even after placing the modifier.


SUMMARY OF THE INVENTION

An aspect of the present invention provides a highly flexible implantable occluding device that can easily navigate the tortuous vessels of the neurovasculature. Additionally, occluding device can easily conform to the shape of the tortuous vessels of the vasculature. Furthermore, the occluding device can direct the blood flow within a vessel away from an aneurysm; additionally such an occluding device allows adequate blood flow to be provided to adjacent structures such that those structures, whether they are branch vessels or oxygen demanding tissues, are not deprived of the necessary blood flow.


The occluding device is also capable of altering blood flow to the aneurysm, yet maintaining the desired blood flow to the surrounding tissue and within the vessel. In this instance, some blood is still allowed to reach the aneurysm, but not enough to create a laminar flow within the aneurysm that would cause injury to its thinned walls. Instead, the flow would be intermittent, thereby providing sufficient time for blood clotting or filler material curing within the aneurysm.


The occluding device is flexible enough to closely approximate the native vasculature and conform to the natural tortuous path of the native blood vessels. One of the significant attributes of the occluding device according to the present invention is its ability to flex and bend, thereby assuming the shape of a vasculature within the brain. These characteristics are for a neurovascular occluding device than compared to a coronary stent, as the vasculature in the brain is smaller and more tortuous.


In general terms, aspects of the present invention relate to methods and devices for treating aneurysms. In particular, a method of treating an aneurysm with a neck comprises deploying a vascular occluding device in the lumen of a vessel at the location of the aneurysm, whereby the blood flow is redirected away from the neck of the aneurysm. The induced stagnation of the blood in the lumen of the aneurysm would create embolization in the aneurysm. The occluding device spans the width of the stem of the aneurysm such that it obstructs or minimizes the blood flow to the aneurysm. The occluding device is very flexible in both its material and its arrangement. As a result, the occluding device can be easily navigated through the tortuous blood vessels, particularly those in the brain. Because the occluding device is flexible, very little force is required to deflect the occluding device to navigate through the vessels of the neurovasculature, which is of significance to the operating surgeon.


A significant feature of the occluding device, apart from its flexibility, is that the occluding device may have an asymmetrical braid pattern with a higher concentration of braid strands or a different size of braid strands on the surface facing the neck of the aneurysm compared to the surface radially opposite to it. In one embodiment, the surface facing the aneurysm is almost impermeable and the diametrically opposed surface is highly permeable. Such a construction would direct blood flow away from the aneurysm, but maintain blood flow to the side branches of the main vessel in which the occluding device is deployed.


In another embodiment, the occluding device has an asymmetrical braid count along the longitudinal axis of the occluding device. This provides the occluding device with a natural tendency to curve, and hence conform to the curved blood vessel. This reduces the stress exerted by the occluding device on the vessel wall and thereby minimizing the chances of aneurysm rupture. Additionally, because the occluding device is naturally curved, this eliminates the need for the tip of the micro-catheter to be curved. Now, when the curved occluding device is loaded on to the tip of the micro-catheter, the tip takes the curved shape of the occluding device. The occluding device could be pre-mounted inside the micro-catheter and can be delivered using a plunger, which will push the occluding device out of the micro-catheter when desired. The occluding device could be placed inside the micro-catheter in a compressed state. Upon exiting the micro-catheter, it could expand to the size of the available lumen and maintain patency of the lumen and allow blood flow through the lumen. The occluding device could have a lattice structure and the size of the openings in the lattice could vary along the length of the occluding device. The size of the lattice openings can be controlled by the braid count used to construct the lattice.


According to aspects of the invention, the occluding device can be used to remodel an aneurysm within the vessel by, for example, neck reconstruction or balloon remodeling. The occluding device can be used to form a barrier that retains occlusion material such as a well known coil or viscous fluids, such as “ONYX” by Microtherapeutics, within the aneurysm so that introduced material will not escape from within the aneurysm due to the lattice density of the occluding device in the area of the aneurysm.


In another aspect of this invention, a device for occluding an aneurysm is disclosed. The device is a tubular with a plurality of perforations distributed on the wall of the member. The device is placed at the base of the aneurysm covering the neck of the aneurysm such that the normal flow to the body of the aneurysm is disrupted and thereby generating thrombus and ultimately occlusion of the aneurysm.


In yet another aspect of this invention, the device is a braided tubular member. The braided strands are ribbons with rectangular cross section, wires with a circular cross section or polymeric strands.


In another embodiment, a device with a braided structure is made in order to conform to a curved vessel in the body, where the density of the braid provides enough rigidity and radial strength. Additionally, the device can be compressed using a force less than 10 grams. This enables the device to be compliant with the artery as the arterial wall is pulsating. Also, the device is capable of bending upon applying a force of less than 5 gram/cm.


Other aspects of the invention include methods corresponding to the devices and systems described herein.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention has other advantages and features which will be more readily apparent from the following detailed description of the invention and the appended claims, when taken in conjunction with the accompanying drawings, in which:



FIG. 1 is an illustration of an aneurysm, branch vessels and blood flow to the aneurysm.



FIGS. 2A and 2B illustrate one embodiment of an occluding device to treat aneurysms.



FIG. 3 is an illustration of the embodiment shown in FIG. 2 in a compressed state inside a micro-catheter.



FIG. 4A is another embodiment of an occluding device for treating aneurysms.



FIGS. 4B and 4C illustrate cross sections of portions of ribbons that can be used to form the occluding device of FIG. 4A.



FIG. 5 shows the occluding device in a compressed state inside a micro-catheter being advanced out of the micro-catheter using a plunger.



FIG. 6 shows the compressed occluding device shown in FIG. 5 deployed outside the micro-catheter and is in an expanded state.



FIG. 7 shows the deployed occluding device inside the lumen of a vessel spanning the neck of the aneurysm, a bifurcation and branch vessels.



FIG. 8 is a schematic showing the occluding device located in the lumen of a vessel and the change in the direction of the blood flow.



FIG. 9 shows the effect of a bending force on a conventional stent compared to the occluding device of the present invention.



FIG. 10 demonstrates the flexibility of the current invention, compared to a traditional stent, by the extent of the deformation for an applied force.



FIG. 11 shows the non-uniform density of the braid that provides the desired curved occluding device.



FIG. 12 illustrates the difference in lattice density or porosity due to the non-uniform density of the braiding of the occluding device.



FIG. 13 shows the varying lattice density occluding device covering the neck of an aneurysm.



FIGS. 14 and 15 show an embodiment of the vascular occluding device where the lattice density is asymmetrical about the longitudinal axis near the aneurysm neck.



FIG. 16 illustrates a bifurcated occluding device according to an embodiment of the present invention in which two occluding devices of lesser densities are combined to form a single bifurcated device.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The devices shown in the accompanying drawings are intended for treating aneurysms. They are generally deployed, using micro-catheters, at the location of a cerebral aneurysm that is intended to be treated. One such system is disclosed in copending U.S. Patent Application titled “System and Method for Delivering and Deploying an Occluding Device Within a Vessel”, (U.S. application Ser. No. 11/136,398) filed on May 25, 2005, which is incorporated herein by reference in its entirety. The embodiments of the endovascular occluding device according to aspects of the present invention is useful for treating cerebral aneurysms that are commonly treated using surgical clips, microcoils or other embolic devices.



FIG. 1 illustrates a typical cerebral aneurysm 10 in the brain. A neck 11 of the aneurysm 10 can typically define an opening of between about 2 to 25 mm. As is understood, the neck 11 connects the vessel 13 to the lumen 12 of the aneurysm 10. As can be seen in FIG. 1, the blood flow 1 within the vessel 13 is channeled through the lumen 12 and into the aneurysm. In response to the constant blood flow into the aneurysm, the wall 14 of lumen 12 continues to distend and presents a significant risk of rupturing. When the blood within the aneurysm 10 causes pressure against the wall 14 that exceeds the wall strength, the aneurysm ruptures. The present invention could prevent such ruptures. Also shown in FIG. 1 are the bifurcation 15 and the side branches 16.



FIG. 2 illustrates one embodiment of an vascular occluding device 20 in accordance with an aspect of the present invention. In the illustrated embodiment, the occluding device 20 has a substantially tubular structure 22 defined by an outer surface 21, an inner surface 24 and a thin wall that extends between the surfaces 21, 24. A plurality of openings 23 extend between the surfaces 21, 24 and allow for fluid flow from the interior of the occluding device 20 to the wall of the vessel. Occluding device 20 is radially compressible and longitudinally adjustable.



FIG. 3 shows a micro-catheter 25 and the occluding device 20 inside the microcatheter 25 in a compressed state prior to being released within the vasculature of the patient.



FIG. 4 illustrates another embodiment of the occluding device 30 having two or more strands of material(s) 31, 32 wound in a helical fashion. The braiding of such material in this fashion results in a lattice structure 33. As can be understood, the dimension of the lattice 33 and the formed interstices 34 is determined, at least in part, by the thickness of the strand materials, the number of strands and the number of helices per unit length of the occluding device 30.


The occluding device 30 is radially compressible and radially expandable without the need for supplemental radially expanding force, such as an inflatable balloon. The occluding device 30 is constructed by winding the two strands (31, 32 in opposite directions. In an embodiment, the strands 31, 32 are in the shape of rectangular ribbon (See FIG. 4C). The ribbons can be formed of known flexible materials including shape memory materials, such as Nitinol, platinum and stainless steel.


The ribbon used as the braiding material for the strands 31, 32 can include a rectangular cross section 35 (FIG. 4C). As shown in FIGS. 4C and 7, the surface 36 that engages an inner surface of the vessel has a longer dimension (width) when compared to the wall 38 that extends between the surfaces 36, 37 (thickness). A ribbon with rectangular cross section has a higher recovery (expansive) force for the same wall thickness when compared to a wire with a circular (round) cross section. Additionally, a flat ribbon allows for more compact compression of the occluding device 20 and causes less trauma to the vascular wall when deployed because it distributes the radial expansion forces over a greater surface area. Similarly, flat ribbons form a more flexible device for a given lattice density because their surface area (width) is greater for a given thickness in comparison to round wire devices.


While the illustrated embodiment discloses a ribbon having a rectangular cross section in which the length is greater than its thickness, the ribbon for an alternative embodiment of the disclosed occluding devices may include a square cross section. In another alternative embodiment, a first portion of the ribbon may include a first form of rectangular cross section and a second portion 39 of the ribbon (FIG. 4B) may include a round, elliptical, oval or alternative form of rectangular cross section. For example, end sections of the ribbons may have substantially circular or oval cross section and the middle section of the ribbons could have a rectangular cross section.


In an alternative embodiment, the occluding device 30 can be formed by winding more than two strands of ribbon. In an embodiment, the occluding device 30 could include as many as sixteen strands of ribbon. By using standard techniques employed in making radially expanding stents, one can create an occluding device 30 with interstices 34 that are larger than the thickness of the ribbon or diameter of the wire. The ribbons can have different widths. In such an embodiment, the different ribbon(s) can have different width(s) to provide structure support to the occluding device 30 and the vessel wall. The ribbons according to the disclosed embodiments can also be formed of different materials. For example, one or more of the ribbons can be formed of a biocompatible metal material, such as those disclosed herein, and one or more of the ribbons can be formed of a biocompatible polymer.



FIG. 5 shows the intravascular occluding device 30 in a radially compressed state located inside the micro-catheter 25. In one embodiment, the occluding device 30 could be physically attached to the catheter tip. This could be accomplished by constraining the occluding device 30 in the distal segment of the micro-catheter. The micro-catheter 25 is slowly advanced over a guidewire (not shown) by a plunger 50 and when the tip of the micro-catheter 25 reaches the aneurysm, the occluding device is released from the tip. The occluding device 30 expands to the size of the vessel and the surface of the occluding device 30 is now apposed to the vessel wall 15 as shown in FIG. 6. Instruments and methods for delivering and deploying the occluding device 30 are disclosed in the above-referenced copending application.


With reference to FIG. 7, the occluding device 30 is deployed inside the lumen of a cerebral vessel 13 with an aneurysm 10. During its deployment, the proximal end 43 of the occluding device 30 is securely positioned against the lumen wall of the vessel 13 before the bifurcation 15 and the distal end 45 of the occluding device 30 is securely positioned against the lumen wall of the vessel 13 beyond the neck 11 of aneurysm 10. After the occluding device 30 is properly positioned at the desired location within the vessel 13 (for example, see FIG. 7), flow inside the lumen of aneurysm 10 is significantly minimized while the axial flow within the vessel 13 is not significantly compromised, in part due to the minimal thickness of the walls 38.


The flow into the aneurysm 10 will be controlled by the lattice density of the ribbons and the resulting surface coverage. Areas having greater lattice densities will have reduced radial (lateral) flow. Conversely, areas of lesser lattice densities will allow significant radial flow through the occluding device 30. As discussed below, the occluding device 30 can have longitudinally extending (lateral) areas of different densities. In each of these areas, their circumferential densities can be constant or vary. This provides different levels of flow through adjacent lateral areas. The location within a vessel of the areas with greater densities can be identified radiographically so that the relative position of the occluding device 30 to the aneurysm 10 and any vascular branches 15, 16 can be determined. The occluding device 30 can also include radiopaque markers.


The reduction of blood flow within the aneurysm 10 results in a reduction in force against the wall 14 and a corresponding reduction in the risk of vascular rupturing. When the force and volume of blood entering the aneurysm 10 is reduced by the occluding device, the laminar flow into the aneurysm 10 is stopped and the blood within the aneurysm begins to stagnate. Stagnation of blood, as opposed to continuous flow through the lumen 12 of the aneurysm 10, results in thrombosis in the aneurysm 10. This also protects the aneurysm from rupturing. Additionally, due to the density of the portion of the occluding device 30 at the bifurcation 15, the openings (interstices) 34 in the occluding device 30 allow blood flow to continue to the bifurcation 15 and the side branches 46 of the vessel. If the bifurcation 15 is downstream of the aneurysm, as shown in FIG. 8, the presence of the occluding device 30 still channels the blood away from the aneurysm 10 and into the bifurcation 15.


The occluding devices described herein have the flexibility necessary to conform to the curvature of the vasculature. This is in contrast to coronary stents that cause the vasculature to conform essentially to their shape. The ability to conform to the shape of the vasculature is more significant for neurovascular occluding devices than coronary stents, as the vasculature in the brain is smaller and more tortuous. Tables 1 and 2 demonstrate these characteristics of the claimed neurovascular occluding device. To demonstrate that the disclosed occluding devices exhibit very desirable bending characteristics, the following experiment was performed. The occluding device made by the inventors was set on a support surface 90 as shown in FIG. 9. About 0.5 inches of the occluding device 30 was left unsupported. Then, a measured amount of force was applied to the unsupported tip until the occluding device was deflected by 90 degrees from the starting point. A similar length of a commercially available coronary stent was subjected to the same bending moment. The results are shown in Table 1. Similar to the reduced compressive force, the occluding device of the present invention required an order of magnitude lower bending moment (0.005 lb-in compared to 0.05 lb-in for a coronary stent).









TABLE 1





Bending Force Required to Bend a 0.5″


Cantilever Made by the Occlusion Device



















Coronary stent
commercially available stent
 0.05 lb-in



Neurovascular
Occluding Device (30)
0.005 lb-in










The occluding devices according to the present invention also provides enhanced compressibility (i.e., for a given force how much compression could be achieved or to achieve a desired compression how much force should be exerted) compared to coronary stents. An intravascular device that is not highly compressible is going to exert more force on the vessel wall compared to a highly compressible device. This is of significant clinical impact in the cerebral vasculature as it is detrimental to have an intravascular device that has low compressibility.









TABLE 2





Compressive Force Required to Compress the Occluding


device to 50% of the Original Diameter (see FIG. 10)



















Coronary stem
(commercially available
 0.2 lb



Neurovascular
Occluding device (30)
0.02 lb











FIGS. 11-13 show an embodiment of the occluding device 60 in which the lattice structure 63 of the occluding device 60 is non-uniform across the length of the occluding device 60. In the mid-section 65 of the occluding device 60, which is the section likely to be deployed at the neck of the aneurysm, the lattice density 63a is intentionally increased to a value significantly higher than the lattice density elsewhere in the occluding device 60. For example, as seen in FIG. 11, lattice density 63A is significantly higher than the lattice density 63 in adjacent section 64. At one extreme, the lattice density (porosity provided by the interstices) could be zero, i.e., the occluding device 60 is completely impermeable. In another embodiment, the lattice density 63A in mid-section 65 could be about 50%, while the lattice density in the other sections 64 of the occluding device is about 25%. FIG. 12 shows such the occluding device 60 in a curved configuration and FIG. 13 shows this occluding device 60 deployed in the lumen of a vessel. FIG. 13 also illustrates the part of the occluding device 60 with increased lattice density 63A positioned along the neck of aneurysm 10. As with any of the disclosed occluding devices, the lattice density of at least one portion of occluding device 60 can be between about 20% and about 80%. The lattice density of these embodiments could be between about 25% and about 50%.


Another embodiment of the occluding device 300 is shown in FIGS. 14 and 15. In this embodiment, the occluding device 300 is deployed in lumen of a vessel with an aneurysm. The occluding device 300 includes a surface 310 that faces the lumen of the aneurysm. This surface 310 has a significantly higher lattice density (smaller and/or fewer interstices) compared to the diametrically opposite surface 320. Due to the higher lattice density of surface 310, less blood flows into the lumen of the aneurysm. However, there is no negative impact on the blood flow to the side branches as the lattice density of the surface 320 facing the side branches is not reduced.


Any of the occluding devices disclosed herein can be used with a second occluding device to create a bifurcated occluding device 400 as shown in FIG. 16. This device could be created in vivo. In forming the occluding device 400, a portion of a first occluding device 410 having a low density can be combined with a portion of a second occluding device 410 that also has a low density. The occluding devices 410, 420 can be any of those discussed herein. After these portions of the two occluding devices 410, 420 are combined in an interwoven fashion to form an interwoven region 425, the remaining portions 414, 424 can branch off in different directions, thereby extending along two branches of the bifurcation. Areas outside of the interwoven region 425 can have greater lattice density for treating an aneurysm or lesser lattice density for allowing flow to branches 15, 16 of the vessel.


The density of the lattice for each of the disclosed occluding devices can be about 20% to about 80% of the surface area of its occluding device. In an embodiment, the lattice density can be about 20% to about 50% of the surface area of its occluding device. In yet another embodiment, the lattice density can be about 20% to about 305 of the surface area of its occluding device.


A typical occluding device having sixteen strand braids with 0.005 inch wide ribbon, 30 picks per inch (PPI) (number of crosses/points of contact per inch), and 0.09 inch outer diameter has approximately 30% of lattice density (surface covered by the ribbon). In the embodiments disclosed herein, the ribbon can be about 0.001 inch thick with a width of between about 0.002 inch to about 0.005 inch. In an embodiment, the ribbon has a thickness of about 0.004 inch. For a 16-strands ribbon that is about 0.001 inch thick and about 0.004 inch wide, the coverage for 50 PPI, 40 PPI, and 30 PPI will have 40%, 32% and 24% approximate surface coverage, respectively. For a 16-strands ribbon that is about 0.001 inch thick and about 0.005 inch wide, the coverage for 50 PPI, 40 PPI, and 30 PPI will be about 50%, 40% and 30% approximate surface coverage, respectively.


In choosing a size for the ribbon, one must consider that, when the ribbons are bundled up, will they traverse through a micro-catheter. For example, sixteen strands of a 0.006 inch wide ribbon may not pass through a micro-catheter having an internal diameter of 0.027 inch or less. However, as the width of ribbons become smaller, the recovery strength may decrease proportionally.


While other strand geometry may be used, these other geometries, such as round, will limit the device due to their thickness dimension. For example, a round wire with a 0.002 inch diameter will occupy up to 0.008 inch in cross sectional space within the vessel. This space can impact and disrupt the blood flow through the vessel. The flow in the vessel can be disrupted with this change in diameter.


Although the detailed description contains many specifics, these should not be construed as limiting the scope of the invention but merely as illustrating different examples and aspects of the invention. It should be appreciated that the scope of the invention includes other embodiments not discussed in detail above. Various other modifications, changes and variations which will be apparent to those skilled in the art may be made in the arrangement, operation and details of the method and apparatus of the present invention disclosed herein without departing from the spirit and scope of the invention as defined in the appended claims. Therefore, the scope of the invention should be determined by the appended claims and their legal equivalents. Furthermore, no element, component or method step is intended to be dedicated to the public regardless of whether the element, component or method step is explicitly recited in the claims.


In the claims, reference to an element in the singular is not intended to mean “one and only one” unless explicitly stated, but rather is meant to mean “one or more.” In addition, it is not necessary for a device or method to address every problem that is solvable by different embodiments of the invention in order to be encompassed by the claims.

Claims
  • 1. A device for positioning within a blood vessel for treatment of an aneurysm, said device including a plurality of woven members, wherein said woven members form a lattice structure along the length of said device, wherein the density of the lattice structure is between about 25 to about 50 picks per inch, each of said woven members comprising an inner surface and an outer surface, said outer surface being configured for positioning adjacent an inner wall of a vessel, and said outer surface forming a portion of an outer circumference of said device between first and second ends of said device, said plurality of woven members forming a plurality of openings extending between adjacent members of the device, said outer surfaces of the plurality of woven members comprising between about 20 percent to about 50 percent of a total circumferential area of said device; wherein the device is configured to freely bend 90 degrees about a fulcrum upon application of a bending moment of 0.005 lb-in to the device, and to be compressed to 50% of an original diameter of the device upon application of a force of less than 10 grams, when the device is fully deployed from a delivery catheter.
  • 2. The device of claim 1, wherein said openings occupy between about 50 to about 80 percent of the total circumferential area of said device.
  • 3. The device of claim 1, comprising a length that can be adjusted during deployment such that the deployed length of the occluding device can be adjusted after the occluding device is loaded within a delivery catheter.
  • 4. The device of claim 1, comprising regions for positioning proximate a branch or feeder portion of the vessel, said regions having a lesser lattice density relative to a region intended to be positioned proximate an aneurysm.
  • 5. The device of claim 1, wherein at least two of the woven members have different cross-sectional dimensions.
  • 6. The device of claim 1, wherein at least two of the woven members are of different metallic materials.
  • 7. The device of claim 1, wherein at least some of the woven members comprise platinum.
  • 8. The device of claim 1, wherein the woven members are round in cross section.
  • 9. A braided device for occluding a portion of a vessel comprising an elongated flexible structure having an asymmetrical braided pattern of woven members, said members having an inner surface and an outer surface, said outer surface being configured for positioning adjacent an inner wall of a vessel, said outer surface forming a portion of an outer circumference of said device between first and second ends of said device, said outer surfaces of the plurality of woven members comprising between about 20 percent to about 50 percent of a total circumferential area of said device; wherein said members form a lattice structure along the length of said device, wherein the density of the lattice structure is between about 25 to about 50 picks per inch, wherein the device, upon application of a bending moment of 0.005 lb-in, is configured to bend 90 degrees about a longitudinal axis of the device; and wherein the device is configured to freely bend about a fulcrum and to be compressed to 50% of an original diameter of the device upon application of a force of less than 10 grams when the device is fully deployed within a vessel.
  • 10. The device of claim 9, wherein a first portion of the braided pattern allows a first amount of radial blood flow to pass there through and a second portion of the braided pattern allows a second amount of radial blood flow there through, said first amount being greater than said second amount; wherein said first and second portions include different lattice densities.
  • 11. The device of claim 9, comprising a length that can be adjusted during deployment such that a deployed length of the occluding device can be adjusted after the occluding device is loaded within a delivery catheter.
  • 12. The device of claim 9, wherein at least two of the woven members have different cross-sectional dimensions.
  • 13. The device of claim 9, wherein at least two of the woven members are of different metallic materials.
  • 14. The device of claim 9, wherein at least some of the woven members comprise platinum.
  • 15. The device of claim 9, wherein the woven members are round in cross section.
  • 16. A braided occlusion device, for occluding an aneurysm in a vessel, the device comprising: an elongate structure having a braided pattern of more than two interwoven members, said interwoven members having an inner surface and an outer surface, said outer surface being configured for positioning adjacent an inner wall of a vessel, said outer surface forming a portion of an outer circumference of said device between first and second ends of said device, said outer surfaces of the plurality of interwoven members comprising between about 20 percent to about 50 percent of a total circumferential area of said device; wherein said interwoven members form a lattice structure along the length of said device, wherein the density of the lattice structure is between about 25 to about 50 picks per inch, the elongate structure having a compressed configuration, for intravascular delivery of the structure to a target site, with a compressed cross-sectional measurement, and an expanded configuration with an expanded cross-sectional measurement greater than the compressed cross-sectional measurement;wherein the elongate structure is configured to change from the compressed configuration to the expanded configuration when unrestrained; andwherein, when in the expanded configuration, a first portion of the elongate structure deflects 90 degrees about a fulcrum and relative to a second portion of the elongate structure when a bending moment of 0.005 lb-in is applied to the first portion, and the elongate structure is configured to be compressed to 50% of an original diameter of the device upon application of a force of less than 10 grams.
  • 17. The device of claim 16, wherein at least two of the interwoven members have different cross-sectional dimensions.
  • 18. The device of claim 16, wherein at least two of the interwoven members are of different metallic materials.
  • 19. The device of claim 16, wherein at least some of the interwoven members comprise platinum.
  • 20. The device of claim 16, wherein the interwoven members are round in cross section.
RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 11/136,395, filed on May 25, 2005, which claims priority benefit of U.S. Provisional Application Ser. No. 60/574,429, filed on May 25, 2004. Each of the aforementioned applications is incorporated by reference in its entirety herein.

US Referenced Citations (588)
Number Name Date Kind
2919467 Mercer Jan 1960 A
4321711 Mano Mar 1982 A
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4538622 Samson et al. Sep 1985 A
4572186 Gould et al. Feb 1986 A
4580568 Gianturco Apr 1986 A
4655771 Wallsten Apr 1987 A
4681110 Wiktor Jul 1987 A
4733665 Palmaz Mar 1988 A
4743251 Barra May 1988 A
4768507 Fischell et al. Sep 1988 A
4776337 Palmaz Oct 1988 A
4856516 Hillstead Aug 1989 A
4954126 Wallsten Sep 1990 A
5011488 Ginsburg Apr 1991 A
5035706 Giantureo et al. Jul 1991 A
5041126 Gianturco Aug 1991 A
5061275 Wallsten et al. Oct 1991 A
5108416 Ryan et al. Apr 1992 A
5160341 Brenneman et al. Nov 1992 A
5180368 Garrison Jan 1993 A
5192297 Hull Mar 1993 A
5197978 Hess Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5209731 Sterman et al. May 1993 A
5242399 Lau et al. Sep 1993 A
5246420 Kraus et al. Sep 1993 A
5246445 Yachia et al. Sep 1993 A
5344426 Lau et al. Sep 1994 A
5360443 Barone et al. Nov 1994 A
5382259 Phelps et al. Jan 1995 A
5401257 Chevalier, Jr. et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5405380 Gianotti et al. Apr 1995 A
5415637 Khosravi May 1995 A
5421826 Crocker et al. Jun 1995 A
5423849 Engelson et al. Jun 1995 A
5449372 Schmaltz et al. Sep 1995 A
5458615 Klemm et al. Oct 1995 A
5476505 Limon Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484444 Braunschweiler et al. Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5507768 Lau et al. Apr 1996 A
5522822 Phelps et al. Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5545208 Wolff et al. Aug 1996 A
5546880 Ronyak et al. Aug 1996 A
5549662 Fordenbacher Aug 1996 A
5562641 Flomenblit et al. Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5591225 Okuda Jan 1997 A
5599291 Balbierz et al. Feb 1997 A
5601593 Freitag Feb 1997 A
5607466 Imbert et al. Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5626602 Gianotti et al. May 1997 A
5628783 Quiachon et al. May 1997 A
5628788 Pinchuk May 1997 A
5632771 Boatman et al. May 1997 A
5632772 Alcime et al. May 1997 A
5636641 Fariabi Jun 1997 A
5637113 Tartaglia et al. Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5645559 Hachtman et al. Jul 1997 A
D381932 Walshe et al. Aug 1997 S
5667522 Flomenblit et al. Sep 1997 A
5674276 Andersen et al. Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690120 Jacobsen et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5695499 Helgerson et al. Dec 1997 A
5700269 Pinchuk et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5709702 Cogita Jan 1998 A
5709703 Lukic et al. Jan 1998 A
5718159 Thompson Feb 1998 A
5725570 Heath Mar 1998 A
5733327 Igaki et al. Mar 1998 A
5735859 Fischell et al. Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5741333 Frid Apr 1998 A
5746765 Kleshinski et al. May 1998 A
5749883 Halpern May 1998 A
5749920 Quiachon et al. May 1998 A
5769884 Solovay Jun 1998 A
5769885 Quiachon et al. Jun 1998 A
5776099 Tremulis Jul 1998 A
5776142 Gunderson Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5797952 Klein Aug 1998 A
5800518 Piplani et al. Sep 1998 A
5810837 Hofmann et al. Sep 1998 A
5817102 Johnson et al. Oct 1998 A
5824039 Piplani et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824042 Lombardi et al. Oct 1998 A
5824044 Quiachon et al. Oct 1998 A
5824058 Ravenscroft et al. Oct 1998 A
5830229 Konya et al. Nov 1998 A
5833632 Jacobsen et al. Nov 1998 A
5836868 Ressemann et al. Nov 1998 A
5843168 Dang Dec 1998 A
5868754 Levine et al. Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5902266 Leone et al. May 1999 A
5902317 Kleshinski et al. May 1999 A
5906640 Penn et al. May 1999 A
5911717 Jacobsen et al. Jun 1999 A
5916194 Jacobsen et al. Jun 1999 A
5919204 Lukic et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5944728 Bates Aug 1999 A
5951599 McCrory Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5957974 Thompson et al. Sep 1999 A
5964797 Ho Oct 1999 A
5980530 Willard et al. Nov 1999 A
5980533 Holman Nov 1999 A
6012277 Prins et al. Jan 2000 A
6014919 Jacobsen et al. Jan 2000 A
6015432 Rakos et al. Jan 2000 A
6017319 Jacobsen et al. Jan 2000 A
6019778 Wilson et al. Feb 2000 A
6019786 Thompson Feb 2000 A
6022369 Jacobsen et al. Feb 2000 A
6024754 Engelson Feb 2000 A
6024763 Lenker et al. Feb 2000 A
6027516 Kolobow et al. Feb 2000 A
6033436 Steinke et al. Mar 2000 A
6039721 Johnson et al. Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6051021 Frid Apr 2000 A
6056993 Leidner et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6074407 Levine et al. Jun 2000 A
6077295 Limon et al. Jun 2000 A
6080191 Summers Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096052 Callister et al. Aug 2000 A
6102942 Ahari Aug 2000 A
6123712 Di Caprio et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6132459 Piplani et al. Oct 2000 A
6139543 Esch et al. Oct 2000 A
6146415 Fitz Nov 2000 A
6149680 Shelso et al. Nov 2000 A
6159228 Frid et al. Dec 2000 A
6161399 Jayaraman Dec 2000 A
6165194 Denardo Dec 2000 A
6165210 Lau et al. Dec 2000 A
6165213 Goicoechea et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6174330 Stinson Jan 2001 B1
6183410 Jacobsen et al. Feb 2001 B1
6183508 Stinson et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6197046 Piplani et al. Mar 2001 B1
6203569 Wijay Mar 2001 B1
6206868 Parodi Mar 2001 B1
6210400 Hebert et al. Apr 2001 B1
6210434 Quiachon et al. Apr 2001 B1
6210435 Piplani et al. Apr 2001 B1
6214038 Piplani et al. Apr 2001 B1
6214042 Jacobsen et al. Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6224609 Ressemann et al. May 2001 B1
6224829 Piplani et al. May 2001 B1
6231598 Berry et al. May 2001 B1
6235050 Quiachon et al. May 2001 B1
6241759 Piplani et al. Jun 2001 B1
6245087 Addis Jun 2001 B1
6245103 Stinson Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6258115 Dubrul Jul 2001 B1
6260458 Jacobsen et al. Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6264671 Stack et al. Jul 2001 B1
6264689 Colgan et al. Jul 2001 B1
6270523 Herweck et al. Aug 2001 B1
6280465 Cryer Aug 2001 B1
6287331 Heath Sep 2001 B1
6290721 Heath Sep 2001 B1
6299636 Schmitt et al. Oct 2001 B1
6302810 Yokota Oct 2001 B2
6302893 Limon et al. Oct 2001 B1
6309353 Cheng et al. Oct 2001 B1
6322576 Wallace et al. Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6322587 Quiachon et al. Nov 2001 B1
6325826 Vardi et al. Dec 2001 B1
6334871 Dor et al. Jan 2002 B1
6336938 Kavteladze et al. Jan 2002 B1
6340367 Stinson et al. Jan 2002 B1
6340368 Verbeck Jan 2002 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350199 Williams et al. Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6355051 Sisskind et al. Mar 2002 B1
6355061 Quiachon et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368344 Fitz Apr 2002 B1
6368557 Piplani et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6375676 Cox Apr 2002 B1
6379618 Piplani et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6389946 Frid May 2002 B1
6395017 Dwyer et al. May 2002 B1
6395021 Hart et al. May 2002 B1
6395022 Piplani et al. May 2002 B1
6398802 Yee Jun 2002 B1
6409683 Fonseca et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6416519 VanDusseldorp Jul 2002 B1
6416536 Yee Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6428489 Jacobsen et al. Aug 2002 B1
6440088 Jacobsen et al. Aug 2002 B1
6443971 Boylan et al. Sep 2002 B1
6443979 Stalker et al. Sep 2002 B1
6454999 Farhangnia et al. Sep 2002 B1
6468301 Amplatz et al. Oct 2002 B1
6477768 Wildner Nov 2002 B1
6478778 Jacobsen et al. Nov 2002 B1
6482221 Hebert et al. Nov 2002 B1
6488705 Schmitt et al. Dec 2002 B2
6491648 Cornish et al. Dec 2002 B1
6494895 Addis Dec 2002 B2
6497711 Plaia et al. Dec 2002 B1
6503450 Afzal et al. Jan 2003 B1
6514261 Randall et al. Feb 2003 B1
6514285 Pinchasik Feb 2003 B1
6524299 Tran et al. Feb 2003 B1
6527763 Esch et al. Mar 2003 B2
6533811 Ryan et al. Mar 2003 B1
6540778 Piplani et al. Apr 2003 B1
6547779 Levine et al. Apr 2003 B2
6551352 Clerc et al. Apr 2003 B2
6572646 Boylan et al. Jun 2003 B1
6576006 Limon et al. Jun 2003 B2
6582460 Cryer Jun 2003 B1
6582461 Burmeister et al. Jun 2003 B1
6589273 McDermott Jul 2003 B1
6592616 Stack et al. Jul 2003 B1
6602271 Adams et al. Aug 2003 B2
6602280 Chobotov Aug 2003 B2
6605110 Harrison Aug 2003 B2
6613075 Healy et al. Sep 2003 B1
6613078 Barone Sep 2003 B1
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6635068 Dubrul et al. Oct 2003 B1
6638243 Kupiecki Oct 2003 B2
6645240 Yee Nov 2003 B2
6646218 Campbell et al. Nov 2003 B1
6652508 Griffin et al. Nov 2003 B2
6652574 Jayaraman Nov 2003 B1
6656212 Ravenscroft et al. Dec 2003 B2
6656218 Denardo et al. Dec 2003 B1
6660024 Flaherty et al. Dec 2003 B1
6660032 Klumb et al. Dec 2003 B2
6663666 Quiachon et al. Dec 2003 B1
6666881 Richter et al. Dec 2003 B1
6669719 Wallace et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673100 Diaz et al. Jan 2004 B2
6679893 Tran Jan 2004 B1
6682557 Quiachon et al. Jan 2004 B1
6685735 Ahari Feb 2004 B1
6689120 Gerdts Feb 2004 B1
6689162 Thompson Feb 2004 B1
6699274 Stinson Mar 2004 B2
6702843 Brown et al. Mar 2004 B1
6709454 Cox et al. Mar 2004 B1
6712834 Yassour et al. Mar 2004 B2
6726700 Levine Apr 2004 B1
6733519 Lashinski et al. May 2004 B2
6740105 Yodfat et al. May 2004 B2
6740112 Yodfat et al. May 2004 B2
6743219 Dwyer et al. Jun 2004 B1
6755855 Yurek et al. Jun 2004 B2
6758885 Leffel et al. Jul 2004 B2
6767361 Quiachon et al. Jul 2004 B2
6773446 Dwyer et al. Aug 2004 B1
6793667 Hebert et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814748 Baker et al. Nov 2004 B1
6818006 Douk et al. Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6849084 Rabkin et al. Feb 2005 B2
6858034 Hijlkema et al. Feb 2005 B1
6860893 Wallace et al. Mar 2005 B2
6860898 Stack et al. Mar 2005 B2
6860899 Rivelli, Jr. Mar 2005 B1
6860900 Clerc et al. Mar 2005 B2
6860901 Baker et al. Mar 2005 B1
6866677 Douk et al. Mar 2005 B2
6866679 Kusleika Mar 2005 B2
6866680 Yassour et al. Mar 2005 B2
6887267 Dworschak et al. May 2005 B2
6890337 Feeser et al. May 2005 B2
6893451 Cano et al. May 2005 B2
6918921 Brady et al. Jul 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6936055 Ken et al. Aug 2005 B1
6955685 Escamilla et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6964670 Shah et al. Nov 2005 B1
6964672 Brady et al. Nov 2005 B2
6969396 Krolik et al. Nov 2005 B2
6976991 Hebert et al. Dec 2005 B2
6989024 Hebert et al. Jan 2006 B2
6994721 Israel Feb 2006 B2
7001422 Escamilla et al. Feb 2006 B2
7004962 Stinson Feb 2006 B2
7004964 Thompson et al. Feb 2006 B2
7011675 Hemerick et al. Mar 2006 B2
7037330 Rivelli, Jr. et al. May 2006 B1
7041129 Rourke et al. May 2006 B2
7066951 Chobotov Jun 2006 B2
7069835 Nishri et al. Jul 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7101392 Heath Sep 2006 B2
7107105 Bjorklund et al. Sep 2006 B2
7118539 Vrba et al. Oct 2006 B2
7118594 Quiachon et al. Oct 2006 B2
7122050 Randall et al. Oct 2006 B2
7137990 Hebert et al. Nov 2006 B2
7166125 Baker et al. Jan 2007 B1
7169170 Widenhouse Jan 2007 B2
7169172 Levine et al. Jan 2007 B2
7172617 Colgan et al. Feb 2007 B2
7192434 Anderson et al. Mar 2007 B2
7195639 Quiachon et al. Mar 2007 B2
7195648 Jones et al. Mar 2007 B2
7201768 Diaz et al. Apr 2007 B2
7201769 Jones et al. Apr 2007 B2
7211109 Thompson May 2007 B2
7213495 McCullagh et al. May 2007 B2
7220271 Clubb et al. May 2007 B2
7235096 Van Tassel et al. Jun 2007 B1
7264632 Wright et al. Sep 2007 B2
7275471 Nishri et al. Oct 2007 B2
7279005 Stinson Oct 2007 B2
7279208 Goffena et al. Oct 2007 B1
7294137 Rivelli, Jr. et al. Nov 2007 B2
7294146 Chew et al. Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7300460 Levine et al. Nov 2007 B2
7306624 Yodfat et al. Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7311031 McCullagh et al. Dec 2007 B2
7320702 Hammersmark et al. Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7331973 Gesswein et al. Feb 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7331985 Thompson et al. Feb 2008 B2
7338518 Chobotov Mar 2008 B2
7438712 Chouinard Oct 2008 B2
7462192 Norton et al. Dec 2008 B2
7468070 Henry et al. Dec 2008 B2
7470282 Shelso Dec 2008 B2
7473271 Gunderson Jan 2009 B2
7491224 Cox et al. Feb 2009 B2
7520893 Rivelli, Jr. Apr 2009 B2
RE40816 Taylor et al. Jun 2009 E
7572288 Cox Aug 2009 B2
7572290 Yodfat et al. Aug 2009 B2
7588597 Frid Sep 2009 B2
7695507 Rivelli, Jr. et al. Apr 2010 B2
7763011 Ortiz et al. Jul 2010 B2
7771463 Ton et al. Aug 2010 B2
7854760 Molaei et al. Dec 2010 B2
7901447 Molaei et al. Mar 2011 B2
7942925 Yodfat et al. May 2011 B2
8007529 Yan Aug 2011 B2
8092486 Berrada et al. Jan 2012 B2
8092508 Leynov et al. Jan 2012 B2
8192484 Frid Jun 2012 B2
8382825 Garcia Feb 2013 B2
8394119 Zaver Mar 2013 B2
8398701 Berez Mar 2013 B2
20010027338 Greenberg Oct 2001 A1
20010044651 Steinke et al. Nov 2001 A1
20010049547 Moore Dec 2001 A1
20010056299 Thompson Dec 2001 A1
20020004667 Adams et al. Jan 2002 A1
20020007194 Plowiecki Jan 2002 A1
20020029061 Amplatz et al. Mar 2002 A1
20020035396 Heath Mar 2002 A1
20020062091 Jacobsen et al. May 2002 A1
20020078808 Jacobsen et al. Jun 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020087119 Parodi Jul 2002 A1
20020111633 Stoltze et al. Aug 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020138133 Lenz et al. Sep 2002 A1
20020143361 Douk et al. Oct 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20020169474 Kusleika et al. Nov 2002 A1
20020173839 Leopold et al. Nov 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193864 Khosravi et al. Dec 2002 A1
20030009215 Mayer Jan 2003 A1
20030023299 Amplatz et al. Jan 2003 A1
20030069522 Jacobsen et al. Apr 2003 A1
20030100945 Yodfat et al. May 2003 A1
20030130684 Brady et al. Jul 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030163155 Haverkost et al. Aug 2003 A1
20030163156 Hebert et al. Aug 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212430 Bose et al. Nov 2003 A1
20040024416 Yodfat et al. Feb 2004 A1
20040030265 Murayama et al. Feb 2004 A1
20040044395 Nelson Mar 2004 A1
20040073300 Chouinard et al. Apr 2004 A1
20040088037 Nachreiner et al. May 2004 A1
20040093010 Gesswein et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040133223 Weber Jul 2004 A1
20040153117 Clubb et al. Aug 2004 A1
20040162606 Thompson Aug 2004 A1
20040172055 Huter et al. Sep 2004 A1
20040186368 Ramzipoor et al. Sep 2004 A1
20040193178 Nikolchev Sep 2004 A1
20040193179 Nikolchev Sep 2004 A1
20040193208 Talpade et al. Sep 2004 A1
20040199243 Yodfat Oct 2004 A1
20040210235 Deshmukh et al. Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040220585 Nikolchev Nov 2004 A1
20040220608 D'Aquanni et al. Nov 2004 A1
20040220663 Rivelli Nov 2004 A1
20040254628 Nazzaro et al. Dec 2004 A1
20040260331 D'Aquanni et al. Dec 2004 A1
20050004595 Boyle et al. Jan 2005 A1
20050021075 Bonnette et al. Jan 2005 A1
20050033407 Weber et al. Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050051243 Forbes Jones et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050059889 Mayer Mar 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050090888 Hines et al. Apr 2005 A1
20050101989 Cully et al. May 2005 A1
20050137680 Ortiz et al. Jun 2005 A1
20050149111 Kanazawa et al. Jul 2005 A1
20050165441 McGuckin et al. Jul 2005 A1
20050177186 Cully et al. Aug 2005 A1
20050192620 Cully et al. Sep 2005 A1
20050209672 George et al. Sep 2005 A1
20050209678 Henkes et al. Sep 2005 A1
20050246010 Alexander et al. Nov 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050283220 Gobran et al. Dec 2005 A1
20050288764 Snow et al. Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060020324 Schmid et al. Jan 2006 A1
20060036309 Hebert et al. Feb 2006 A1
20060089703 Escamilla et al. Apr 2006 A1
20060095213 Escamilla et al. May 2006 A1
20060111771 Ton et al. May 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116750 Hebert et al. Jun 2006 A1
20060184238 Kaufmann et al. Aug 2006 A1
20060195118 Richardson Aug 2006 A1
20060206148 Khairkhahan et al. Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060206201 Garcia et al. Sep 2006 A1
20060212127 Karabey et al. Sep 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20070021816 Rudin Jan 2007 A1
20070043419 Nikolchev et al. Feb 2007 A1
20070055365 Greenberg et al. Mar 2007 A1
20070060994 Gobran et al. Mar 2007 A1
20070073379 Chang Mar 2007 A1
20070077347 Richter Apr 2007 A1
20070100321 Rudakov et al. May 2007 A1
20070100414 Licata et al. May 2007 A1
20070100430 Rudakov et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070119295 McCullagh et al. May 2007 A1
20070123969 Gianotti May 2007 A1
20070162104 Frid Jul 2007 A1
20070167980 Figulla et al. Jul 2007 A1
20070198076 Hebert et al. Aug 2007 A1
20070203559 Freudenthal et al. Aug 2007 A1
20070203563 Hebert et al. Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208373 Zaver et al. Sep 2007 A1
20070208376 Meng Sep 2007 A1
20070208415 Grotheim et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070233175 Zaver et al. Oct 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070255386 Tenne Nov 2007 A1
20070255388 Rudakov et al. Nov 2007 A1
20070280850 Carlson Dec 2007 A1
20070299500 Hebert et al. Dec 2007 A1
20070299501 Hebert et al. Dec 2007 A1
20070299502 Hebert et al. Dec 2007 A1
20080015673 Chuter Jan 2008 A1
20080033341 Grad Feb 2008 A1
20080033526 Atladottir et al. Feb 2008 A1
20080039930 Jones et al. Feb 2008 A1
20080039933 Yodfat et al. Feb 2008 A1
20080082154 Tseng et al. Apr 2008 A1
20080114391 Dieck et al. May 2008 A1
20080125855 Henkes et al. May 2008 A1
20080208320 Tan-Malecki et al. Aug 2008 A1
20080221666 Licata et al. Sep 2008 A1
20080221670 Clerc et al. Sep 2008 A1
20080221671 Chouinard et al. Sep 2008 A1
20080255654 Hebert et al. Oct 2008 A1
20080255655 Kusleika et al. Oct 2008 A1
20080262590 Murray Oct 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080275497 Palmer et al. Nov 2008 A1
20080275498 Palmer et al. Nov 2008 A1
20080294104 Mawad Nov 2008 A1
20080300667 Hebert et al. Dec 2008 A1
20090024202 Dave et al. Jan 2009 A1
20090024205 Hebert et al. Jan 2009 A1
20090030496 Kaufmann et al. Jan 2009 A1
20090030497 Metcalf et al. Jan 2009 A1
20090054981 Frid et al. Feb 2009 A1
20090099643 Hyodoh et al. Apr 2009 A1
20090105802 Henry et al. Apr 2009 A1
20090105803 Shelso Apr 2009 A1
20090125093 Hansen May 2009 A1
20090192536 Berez et al. Jul 2009 A1
20090192587 Frid Jul 2009 A1
20090198318 Berez et al. Aug 2009 A1
20090270974 Berez et al. Oct 2009 A1
20090287241 Berez et al. Nov 2009 A1
20090287288 Berez et al. Nov 2009 A1
20090288000 McPherson Nov 2009 A1
20090292348 Berez et al. Nov 2009 A1
20090318947 Garcia et al. Dec 2009 A1
20090319017 Berez et al. Dec 2009 A1
20100010624 Berez et al. Jan 2010 A1
20100061604 Nahm et al. Mar 2010 A1
20100063531 Rudakov et al. Mar 2010 A1
20100076317 Babic et al. Mar 2010 A1
20100152834 Hannes et al. Jun 2010 A1
20100174269 Tompkins et al. Jul 2010 A1
20100174309 Fulkerson et al. Jul 2010 A1
20100179583 Carpenter et al. Jul 2010 A1
20100179647 Carpenter et al. Jul 2010 A1
20100198334 Yodfat et al. Aug 2010 A1
20100204779 Schuessler et al. Aug 2010 A1
20100222864 Rivelli, Jr. et al. Sep 2010 A1
20100256733 Schuessler Oct 2010 A1
20100280587 Ortiz et al. Nov 2010 A1
20100318174 Shaolian et al. Dec 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20110016427 Douen Jan 2011 A1
20110040372 Hansen et al. Feb 2011 A1
20110046718 Cattaneo et al. Feb 2011 A1
20110046720 Shalev et al. Feb 2011 A1
20110166592 Garcia et al. Jul 2011 A1
20110179389 Douen Jul 2011 A1
20110184451 Sahl Jul 2011 A1
20110190862 Bashiri et al. Aug 2011 A1
20110245862 Dieck et al. Oct 2011 A1
20110270178 Fiorella et al. Nov 2011 A1
20120035643 Khairkhahan et al. Feb 2012 A1
20120041459 Fiorella et al. Feb 2012 A1
20120158124 Zaver et al. Jun 2012 A1
20120253454 Costello Oct 2012 A1
20120290067 Cam et al. Nov 2012 A1
20120316638 Grad et al. Dec 2012 A1
20120323309 Cattaneo Dec 2012 A1
20130172975 Berez et al. Jul 2013 A1
Foreign Referenced Citations (51)
Number Date Country
101472537 Jul 2009 CN
855170 Jul 1998 EP
1683541 Jul 2006 EP
1942972 Jul 2008 EP
1872742 May 2009 EP
2 078 512 Jul 2009 EP
2556210 Jun 1985 FR
2556210 Apr 1988 FR
10-328216 Dec 1998 JP
11-506686 Jun 1999 JP
11-299901 Nov 1999 JP
2001-509412 Jul 2001 JP
2002-253682 Sep 2002 JP
2003520103 Jul 2003 JP
2004-049585 Feb 2004 JP
2005-074230 Mar 2005 JP
2006-506201 Feb 2006 JP
2008-541832 Nov 2008 JP
4673987 Apr 2011 JP
WO-8800813 Feb 1988 WO
WO-9509586 Apr 1995 WO
WO-9532757 Dec 1995 WO
WO-9804211 Feb 1998 WO
9847447 Oct 1998 WO
WO-9902092 Jan 1999 WO
9905977 Feb 1999 WO
WO-9949812 Dec 1999 WO
WO-0105331 Jan 2001 WO
WO-0152771 Jul 2001 WO
WO-0205729 Jan 2002 WO
WO-0247579 Jun 2002 WO
WO-0254988 Jan 2003 WO
WO-03007840 Jan 2003 WO
WO-03043527 May 2003 WO
WO-03049600 Jun 2003 WO
03057079 Jul 2003 WO
WO-03073963 Sep 2003 WO
WO-2004087006 Nov 2004 WO
WO-2005023149 Dec 2005 WO
2006034140 Mar 2006 WO
WO-2006073745 Jul 2006 WO
WO-2006127005 Nov 2006 WO
2007122396 Nov 2007 WO
2008005898 Jan 2008 WO
WO-2007139689 Sep 2008 WO
WO-2007139699 Sep 2008 WO
WO-2005115118 Jul 2009 WO
WO-2009105710 Aug 2009 WO
2010127838 Nov 2010 WO
2011023105 Mar 2011 WO
2011134663 Nov 2011 WO
Non-Patent Literature Citations (21)
Entry
Benndorf, et al. Treatment of a Ruptured Dissecting Vertebral Artery Aneurysm with Double Stent Placement: Case Report AJNR Am J Neuroradiol, Nov.-Dec. 2001, vol. 22, pp. 1844-1848.
Brilstra, et al., Treatment of Intracranial Aneurysms by Embolization with Coils: A Systematic Review, Stroke, Journal of the American Heart Association, 1999, vol. 30, pp. 470-476.
Ferguson, Gary, Physical Factors in the Initiation, Growth and Rupture of Human Intracranial Saccular Ameurysms, J. Neurosurg, Dec. 1972, vol. 37, pp. 666-667.
Geremia, et al., Embolization of Experimentally Created Aneurysms with Intravascular Stent Devices, ANJR American Journal of Neuroradiology, Aug. 1994, vol. 15, pp. 1223-1231.
Geremia, et al., Occlusion of Experimentally Created Fusiform Aneurysms with Porous Metallic Stents, ANJR Am J Neuroradiol, Apr. 2000, Issue 21, pp. 739-745.
Lanzino, et al., Efficacy and Current Limitations of Intravascular Stents for Intracranial Internal Carotid, Vertebral, and Basilar Artery Aneurysms, Journal of Neurosurgery, Oct. 1999, vol. 91, Issue 4, pp. 538-546.
Lieber, et al., Alteration of Hemodynamics in Aneurysm Models by Stenting: Influence of Stent Porosity, Ann of Biomedical Eng., 1997, vol. 25, pp. 460-469, Buffalo, NY.
Lieber, et al., The Physics of Endoluminal Stenting in the Treatment of Cerebrovascular Aneurysms, Neurological Research, 2002, Vcol 24, Issue Supplement 1, pp. S32-S42.
Moss, et al., Vascular Occlusion with a Balloon-Expadable Stent Occluder, Radiology, May 1994, vol. 191, Issue 2, pp. 483-486.
Pereira, Edgard, History of Endovascular Aneurysm Occlusion, Management of Cerebral Aneurysms, 2004, pp. 11-26.
Qureshi, Adnan, Endovascular Treatment of Cerebrovascular Diseases and Intracranial Neoplasms, The Lancelet, Mar. 2004, vol. 363, pp. 804-813.
Steiger, Pathophysiology of Development and Rupture of Cerebral Aneurysms, Acta Nurochirurgica, Mar. 1990, vol. Supplementum 48, pp. in 62 pages.
Tenaglia, et al., Ultrasound Guide Wire-Directed Stent Deployment, Duke University Medical Center, Department of Medicine, 1993 USA.
Yu, et al., A Steady Flow Analysis on the Stented and Non-Stented Sidewall Aneurysm Models, Medical Engineering and Physics, Apr. 1999, Issue 21, pp. 133-141.
U.S. Appl. No. 13/644,854, filed Oct. 31, 2012.
U.S. Appl. No. 13/669,944, filed Nov. 6, 2012.
U.S. Appl. No. 13/826,971, filed Mar. 14, 2013.
U.S. Appl. No. 13/775,592, filed Feb. 25, 2013.
U.S. Appl. No. 13/845,162, filed Mar. 18, 2013.
U.S. Appl. No. 13/827,030, filed Mar. 14, 2013.
U.S. Appl. No. 13/826,147, filed Mar. 14, 2013.
Related Publications (1)
Number Date Country
20140114342 A1 Apr 2014 US
Provisional Applications (1)
Number Date Country
60574429 May 2004 US
Continuations (1)
Number Date Country
Parent 11136395 May 2005 US
Child 13845162 US